Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta, NYU Medical Center, High Throughput Genomics, UCSD, LabCorp, Ipsogen, Empire Genomics, Affymetrix, DSM Venturing

Premium
Rosetta, NYUMedicalCenter Collaborate to Develop MicroRNA-Based Dx for Melanoma
 
Rosetta Genomics announced this week it will be working with NYU Medical Center to study microRNA profiles and develop a diagnostic test for melanoma.
 
It wasn’t immediately clear what NYU Medical Center’s role will be in the collaboration. However, Rosetta Genomics said its diagnostic technology will “enable it to discover the majority of known microRNA sequences for which it has submitted a series of patent applications.”
 
The company plans to screen more than 700 microRNAs, many of which are not publicly available yet, in order to identify the right signature that will lead to the development of a prognostic indicator test for melanomas.
 
In addition to developing the melanoma diagnostic test, which is still in its early stages, Rosetta Genomics will launch three diagnostic products next year, including a test for cancer of unknown primary site and two differential diagnostics for lung cancer.
“The company will continue gradually to expand its pipeline with more diagnostic and eventually therapeutic applications,” Rosetta said in a statement.
 
"This collaboration with NYU will give both organizations an opportunity to understand a deadly cancer in new ways and to try to save patient lives," said Amir Avniel, Rosetta Genomics’ CEO, in a statement. 
 

 
High Throughput Genomics, UCSD Team on Diabetes Gene Studies
 
High Throughput Genomics said this week it will collaborate with the University of California, San Diego, to generate arrays from mouse tissue samples and from cell lysates to evaluate genes tied to inflammation and insulin production.
 
Under the agreement, HTG will work with the UCSD Department of Medicine's Division of Endocrinology and Metabolism to study how insulin resistance and inflammation function in diabetes.
 
The agreement also calls for HTG to provide its ArrayPlate lysis-only quantitative Nuclease Protection Assay technology, or qNPA, platform, which the company said allows researchers to test any sample, including fixed tissues, without extraction or target amplification.
 

 
LabCorp to Offer Ipsogen's JAK2 Leukemia Assay in US via CLIA Labs
 
LabCorp will offer one of Ipsogen’s blood-based cancer assays in the United States under a new non-exclusive license agreement, Ispogen said this week.
 
Ipsogen, based in Marseilles, France, said the assay classifies and diagnoses a group of leukemias caused by variations in the JAK2 gene, for which the company holds exclusive, worldwide intellectual property rights.
 
The license will allow LabCorp to offer the test, which is registered as an IVD in Europe, through its CLIA-registered US labs.
 
The company said that a “high proportion” of individuals with myeloproliferative disorders have a dominant mutation of the JAK2 gene.
 
Financial terms of the agreement were not released.
 
Last month, Ispogen granted Warnex rights to offer the JAK2 assay in Canada.
 

 
Empire Genomics Licenses Affy's Microarray Patents for Dx Development
 
Affymetrix has licensed several of its microarray-related patents to Empire Genomics, Affy said last week.
 
Under the non-exclusive agreement, Empire Genomics, a Buffalo, NY-based molecular diagnostics company, will use Affy’s technology to manufacture, use, and sell DNA chips and related products and services for comparative genomic hybridization, Affy said.
 
Financial terms of the agreement were not released.
 

 
Dutch VC Shop Invests $2.7M in Jurilab to Help Drive Metabolic Syndrome Research
 
DSM Venturing has invested €2 million ($2.7 million) in Finnish diagnostics company Jurilab, DSM said last week.
 
Jurilab specializes in disease markers and pathways, drug targets, and diagnostic content for metabolic syndrome. DSM, a financing branch of the Dutch company Royal DSM, said it believes that Jurilab’s access to the “relatively homogenous” East Finland founder population and its databank make its approach “faster, more informative, and more cost-effective than many traditional screening approaches."
 
Metabolic syndrome is sometimes used as an umbrella term to cover obesity, type 2 diabetes, dyslipidemia, and hypertension, DSM said. The market for diagnostics and personalized approaches to these diseases will continue to grow as populations age and become more health conscious, DSM said.
 
DSM last year put $2.6 million into its nutrigenomics programs through an investment in molecular diagnostics company Integragen.

Filed under